Covered recipient · General Payments record
ERROL RUSHOVICH
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$5,522.21
- Reported across 294 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $263.35 | 13 |
| Long term medical supply or device loan | $29.97 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $62.41 | 3 |
| ABBVIE INC. | $56.28 | 3 |
| Novo Nordisk AS | $43.72 | 2 |
| Alexion Pharmaceuticals, Inc. | $40.28 | 2 |
| Radius Health, Inc. | $34.93 | 1 |
| CeQur Corporation | $19.29 | 1 |
| Amneal Pharmaceuticals LLC | $18.49 | 1 |
| Lilly USA, LLC | $17.92 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $18.10 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124888002 | CMS |
| Abbott Laboratories | $14.34 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124888004 | CMS |
| Abbott Laboratories | $29.97 | 04/22/2024 | Long term medical supply or device loan | Undisputed | 01/23/2026 | 1125393601 | CMS |
| ABBVIE INC. | $18.59 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105989583 | CMS |
| ABBVIE INC. | $18.08 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105989585 | CMS |
| ABBVIE INC. | $19.61 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105989587 | CMS |
| Alexion Pharmaceuticals, Inc. | $18.89 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093917060 | CMS |
| Alexion Pharmaceuticals, Inc. | $21.39 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093944203 | CMS |
| Amneal Pharmaceuticals LLC | $18.49 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139200282 | CMS |
| CeQur Corporation | $19.29 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126844552 | CMS |
| Lilly USA, LLC | $17.92 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136167492 | CMS |
| Novo Nordisk Inc | $22.16 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096885793 | CMS |
| Novo Nordisk Inc | $21.56 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097538085 | CMS |
| Radius Health, Inc. | $34.93 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089950999 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.